RPCEC00000257Not yet recruitingPhase 1
Bioequivalence study of two formulations of Clopidogrel in healthy volunteers
Center for Pharmaceutical Research and Development, Havana, Cuba.0 sites24 target enrollmentStarted: October 17, 2017Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 24
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized controlled trial. Masking: Double Blind. Control group: Active. Assignment: Crossover. Purpose: Treatment
Eligibility Criteria
- Ages
- 18 years to 50 years (—)
- Sex
- All
Inclusion Criteria
- •1. Written informed consent.
- •2. Aged between 18-50 years.
- •3. Volunteers of both sexes.
- •4- Volunteers’ weight: +/- 15% of their ideal weight for height.
- •5- Failure to submit evidence of organic or psychiatric disease according to interrogation, physical examination and laboratory tests.
- •6- Not have evidence or history of diseases such as bronchial asthma, hypertension, bad-absorption syndrome, peptic ulcer or duodenal present, liver failure, kidney failure, severe allergic reactions, atopic dermatitis, cardiovascular disorders, diabetes mellitus.
- •7- Satisfactory physical examination.
- •8- Present vital signs values within the following reference ranges. Systolic blood pressure between 90 and 130 mm Hg and diastolic blood pressure between 60 and 80 mm Hg, heart rate between 60 to 100 beats per minute, respiratory rate between 12 to 20 breaths per minute.
- •9- Not having consumed alcohol, drinks containing xanthines (tea, coffee, and cola) and carbonated beverages three days before the start of each period and during it.
- •10- Smoking or non-smoking subjects. A record of cigars use will be made.
- •11- Laboratory results within the acceptance range. For some parameters such as blood counts with differential, urine, etc., a result found outside the reference range will be carefully evaluated for clinical meaning by the clinical investigator.
- •12- Post-menopausal women (age 45 or older with at least two years of amenorrhea) or documented history of hysterectomy and / or oophorectomy double sex.
- •13- Female subject within childbearing age who use a (non-hormonal) contraceptive effective method at least 14 days before the first dose of product research and continued throughout the study. The decision to use effective contraception will be conducted by the principal investigator or clinical investigator responsible of medical care.
Exclusion Criteria
- •1- Failure to comply with any of the inclusion criteria.
- •2- History of allergy, idiosyncratic or hypersensitivity to diltiazem or the components of the formulations under study.
- •3- Refer some viral disease in the last 7 days.
- •4- To be ingesting some medication 15 days (or for 5 half-lives) before the first dose of product research or nonprescribed or free drugs (OTC drugs) or herbal medicines / dietary supplements in a period seven days before the first dose of research products until the end of the study.
- •5- Total bilirubin values hihger than 1.5 times the upper limit of the reference range.
- •6- Serum creatinin values higher than 1.5 times the upper limit of the reference range.
- •7- Values of AST, ALT and GGT higher than 2 times the upper limit of the reference range.
- •8- Positive for hepatitis B and C virus, HIV or serology.
- •9- History of thrombotic events.
- •10- History of alcoholism in the past 6 months (not less consumption ¼ bottle of rum or one (1) bottle of wine or three (3) beers in a higher frequency of twice a week.
- •11- Patients with a history of drug consumption dependence or drug abuse.
- •12- Blood donation 3 months prior to baseline.
- •13- Participation in a clinical trial in the last 6 months.
- •14- To be undergone major surgery within 6 months prior to baseline.
- •15- Pregnancy and / or breastfeeding.
- •16- History or antecedents of drug allergy.
Investigators
Similar Trials
Recruiting
Phase 1
In vivo bioequivalence study of a new clobetasol propionate 0.05% topical cream compared to DERMOVAL® 0.05% cream using the skin blanching bioassay in healthy subjects.corticosteroid-sensitive dermatosisCTIS2023-504879-24-00Substipharm102
Active, not recruiting
Not Applicable
A Randomised Comparison Between 150 mg/die Clopidogrel Maintenance Dose Versus 75 mg/die in Patients with ST Segment Elevation Acute Myocardial Infarction: Effects on Platelet Aggregation and Inflammatory Markers - NDST Segment Elevation Acute Myocardial InfarctionMedDRA version: 6.1Level: PTClassification code 10000891EUCTR2007-002664-10-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI40
Not yet recruiting
Phase 1
A Bioequivalence Study of Dabigatran Etexilate Capsules under Fasting ConditionsPrevention of venous thromboembolism (VTE) in adult patients who have undergone elective hip or knee replacement surgery, treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), prevention of recurrent DVT and PE, and prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF)Bioequivalence, Dabigatran, Dabigatran etexilate, generic dabigatran, generic dabigatran etexilate, pharmacokineticsTCTR20210819001MSN Laboratories Private Limited42
Not yet recruiting
Phase 1
A Bioequivalence Study of Two Formulations of 5 mg Montelukast Chewable Tablets in Healthy Thai Volunteers under Fasting ConditionsHealthy Thai VolunteersTCTR20210720012Siriraj Institute of Clinical Research (SICRES)28
Completed
Phase 2
Comparative pharmaceutico-analytical study of two types of kanta loha bhasmas and their clinical efficacy in the management of type 2 diabetesCTRI/2020/05/025358Institute for Post Graduate Teaching and Research in Ayurveda60